Clinical-grade human umbilical cord mesenchymal stem cells affect the improvement of neurological function in rats with traumatic brain injury

doi:10.12307/2023.231

Abstract

Abstract: BACKGROUND: Traumatic brain injury is one of the most serious neurological diseases with the highest incidence in the world, and there is no effective therapy at present. Studies have shown that mesenchymal stem cells have a certain repair effect on traumatic brain injury.
OBJECTIVE: To investigate the effects of clinical-grade umbilical cord mesenchymal stem cells on the improvement of neurological function in rats with traumatic brain injury.
METHODS: Forty-five rats were divided into three groups, namely sham operation group (n=15), model group (n=15) and stem cell group (n=15). Except the sham operation group, the modified Feeney free fall method was used to establish the traumatic brain injury model in the model and stem cell groups. At 24 hours after model establishment, the model group was implanted with 20 μL normal saline; and the stem cell group was implanted with 20 μL human umbilical cord mesenchymal stem cell suspension, a total of 1×106 cells. At 1, 3, 7, 14, and 21 days after cell transplantation, the neural function of the rats was evaluated by modified neurological severity scores. At 21 days after injection, the ratio of Bcl-2/Bax mRNA was detected by RT-qPCR. The expression levels of gliocyte markers GFAP and IBA1 were detected by RT-qPCR and immunofluorescence method. At 21 days after injection, plasma levels of tumor necrosis factor alpha, interleukin 6 and interleukin 10 were determined by ELISA. Hematoxylin-eosin staining was used to observe the brain tissue structure.
RESULTS AND CONCLUSION: (1) Compared with the model group, modified neurological severity score was significantly lower and the motor function was significantly improved in the stem cell group. (2) Compared with the model group, Bcl-2/Bax mRNA ratio was significantly increased in brain tissue, the expression of GFAP and IBA1 was significantly decreased in the stem cell group, while the expression of tumor necrosis factor alpha, interleukin 6 and interleukin 10 in plasma was not significantly different. (3) Hematoxylin-eosin staining showed that the defect area and edema of brain tissue and neuronal apoptosis were improved in different degrees in the stem cell group. (4) The results show that clinical-grade human umbilical cord mesenchymal stem cells can promote neurological function recovery, reduce neuronal apoptosis and inhibit glial overactivation after traumatic brain injury.

Key words: umbilical cord mesenchymal stem cell, traumatic brain injury, neurological function recovery, glial cell, apoptosis

CLC Number:

Cui Lianxu, Jiang Wenkang, Lu Dahong, Xu Junrong, Liu Xiaocui, Wang Bingyun. Clinical-grade human umbilical cord mesenchymal stem cells affect the improvement of neurological function in rats with traumatic brain injury[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(6): 835-839.

Figures/Tables 8

References

[1] WANG KK, YANG Z, ZHU T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18(2): 165-180.
[2] YAMAMOTO S, DEWITT DS, PROUGH DS. Impact & Blast Traumatic Brain Injury: Implications for Therapy. Molecules. 2018;23(2):245.
[3] LUCKE-WOLD BP, LOGSDON AF, NGUYEN L, et al. Supplements, nutrition, and alternative therapies for the treatment of traumatic brain injury. Nutr Neurosci. 2018;21(2):79-91.
[4] SIMON DW, MCGEACHY MJ, BAYIR H, et al. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13(3): 171-191.
[5] WESTON NM, SUN D. The Potential of Stem Cells in Treatment of Traumatic Brain Injury. Curr Neurol Neurosci Rep. 2018;18(1):1.
[6] LV FJ, TUAN RS, CHEUNG KM, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408-1419.
[7] GALIPEAU J, SENSÉBÉ L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018;22(6):824-833.
[8] SZYDLAK R. Mesenchymal stem cells’ homing and cardiac tissue repair. Acta Biochim Pol. 2019;66(4):483-489.
[9] DING DC, CHANG YH, SHYU WC, et al. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-347.
[10] WANG G, WU HL, LIU YP, et al. Pre-clinical study of human umbilical cord mesenchymal stem cell transplantation for the treatment of traumatic brain injury: safety evaluation from immunogenic and oncogenic perspectives. Neural Regen Res. 2022;17(2):354-361.
[11] MUSHAHARY D, SPITTLER A, KASPER C, et al. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2018; 93(1):19-31.
[12] CHEN L, XIANG E, LI C, et al. Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Nephrocyte Injury and Proteinuria in a Diabetic Nephropathy Rat Model. J Diabetes Res. 2020;2020:8035853.
[13] WATSON N, DIVERS R, KEDAR R, et al. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015;17(1):18-24.
[14] CAO TT, CHEN H, PANG M, et al. Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury. Neural Regen Res. 2022;17(8):1785-1794.
[15] MAUMUS M, PERS YM, RUIZ M, et al. Mesenchymal stem cells and regenerative medicine: future perspectives in osteoarthritis. Med Sci (Paris). 2018;34(12):1092-1099.
[16] SHEN J, CAO D, SUN JL. Ability of human umbilical cord mesenchymal stem cells to repair chemotherapy-induced premature ovarian failure. World J Stem Cells. 2020;12(4):277-287.
[17] KARVE IP, TAYLOR JM, CRACK PJ. The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol. 2016;173(4):692-702.
[18] YANG QQ, ZHOU JW. Neuroinflammation in the central nervous system: Symphony of glial cells. Glia. 2019;67(6):1017-1035.
[19] ALLEN NJ, LYONS DA. Glia as architects of central nervous system formation and function. Science. 2018;362(6411):181-185.
[20] SHINOZAKI Y, SHIBATA K, YOSHIDA K, et al. Transformation of Astrocytes to a Neuroprotective Phenotype by Microglia via P2Y1 Receptor Downregulation. Cell Rep. 2017;19(6):1151-1164.
[21] DONNELLY CR, ANDRIESSEN AS, CHEN G, et al. Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain. Neurotherapeutics. 2020; 17(3):846-860.
[22] WILTON DK, DISSING-OLESEN L, STEVENS B. Neuron-Glia Signaling in Synapse Elimination. Annu Rev Neurosci. 2019;42:107-127.
[23] DINET V, PETRY KG, BADAUT J. Brain-Immune Interactions and Neuroinflammation After Traumatic Brain Injury. Front Neurosci. 2019; 13:1178.
[24] KIM S, KIM YE, HONG S, et al. Reactive microglia and astrocytes in neonatal intraventricular hemorrhage model are blocked by mesenchymal stem cells. Glia. 2020;68(1):178-192.
[25] LI Z, SONG Y, HE T, et al. M2 microglial small extracellular vesicles reduce glial scar formation via the miR-124/STAT3 pathway after ischemic stroke in mice. Theranostics. 2021;11(3):1232-1248.
[26] CHEN KH, SHAO PL, LI YC, et al. Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Effectively Protected the Brain Architecture and Neurological Function in Rat After Acute Traumatic Brain Injury. Cell Transplant. 2020;29:963689720929313.